Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy
Key takeaways
- Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc.
- The candidate drug has demonstrated significant, clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with the standard of care.
- According to RBC Capital, the positive clinical trials strengthen Revolution Medicine’s position in the pancreatic ductal adenocarcinoma market.
Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy Abdul Rahman Sun, June 14, 2026 at 2:30 AM GMT+7 2 min read RVMD Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best hot stocks to buy for June. On June 8, RBC Capital reiterated an Outperform rating on Revolution Medicines Inc. (NASDAQ:RVMD) and a $182 price target.
The research firm remains bullish on the company’s outlook for candidate drug daraxonrasib (formerly referred to as daraxibart), which demonstrated an overall survival benefit in patients with metastatic pancreatic cancer. The candidate drug has demonstrated significant, clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with the standard of care.
According to RBC Capital, the positive clinical trials strengthen Revolution Medicine’s position in the pancreatic ductal adenocarcinoma market. Consequently, it expects the company to become a leader in the space on daraxibart, achieving $5.6 billion in peak sales by combining with other treatment regimens.